Table 2. Virologic and immunologic status of the complete study population with available data before and during LPV/r exposure.
| Patients | Mean values | At baseline (Before LPV/r exposure) | During LPV/r exposure (last clinical report) | Δ | p-value |
|---|---|---|---|---|---|
| Group 1 | VL suppression | 0 patientsa | 87.5% patientsb | - | - |
| CD4 cells | 1280.1; IQR [265–1906.2]b | 1258.5; IQR [860.5–1692.7]c | -21.6 | NS | |
| CD4% | 23.2%; IQR [9–34]b | 31.4%; IQR [24.4–38.3]d | +8.2% | 0.03 | |
| CD8% | 33.7%; IQR [25.9–38.4]b | 37.8%; IQR [37.8–46]e | +4.1% | 0.03 | |
| Group 2 | VL suppression | 38.9% patientsf | 68.6% patientsg | - | - |
| CD4 cells | 1220.1; IQR[604.5–1621.5]f | 928.8; IQR [647.8–1194.1]b | -291.3 | NS | |
| CD4% | 28.9%; IQR [20.2–37.7]f | 33%; IQR [25.5–39.4]h | +4.1% | NS | |
| CD8% | 38.4%; IQR [30.1–45.9]f | 40.8%; IQR [27–49]i | +2.4 | NS | |
| Group 3 | VL suppression | 28.8% patientsj | 64.8% patientsk | - | - |
| CD4 cells | 733.8; IQR [426.5–952]l | 790.7; IQR [551.7–1000.8]m | +56.9 | NS | |
| CD4% | 26.3%; IQR [18.1–35]n | 30%; IQR [23.9–36.65]o | +3.7% | 0.005 | |
| CD8% | 43.4%; IQR [34.9–51.1]n | 45.5%; IQR [34.5–55.2]p | +2.1 | NS | |
| Total | VL suppression | 2.8% patientsq | 19.6% patientsr | - | - |
| CD4 cells | 898.5; IQR [438.7–1121.5]s | 910.8; IQR [608.1–1186.6]t | +12.3 | NS | |
| CD4% | 26.4%; IQR [17–35]u | 30.7%; IQR [23.99–37.59]v | +4.3% | 0.0001 | |
| CD8% | 40.8%; IQR [32.5–48]w | 43.7%; IQR [32–53.7]x | +2.9 | 0.05 | |
| With resistance data | CD4 cells | 888.1; IQR [398–1118] Ω | 782.7; IQR [271–1033.5]α | -105.4 | NS |
| CD4% | 26.5%; IQR [18–34.6]μ | 25.4%; IQR [17.2–34.4] Ф | -1.1% | NS | |
| CD8% | 42.6%; IQR [30.75–53.1]π | 47.2%; IQR [34.6–61]α | +4.6% | NS |
Baseline, the last available data before LPV/r exposure. VL, virus load; IQR, interquartile range; Δ, difference between the available data before and during LPV/r experience. Rates calculated with available data in. 28a, 32b, 20c, 26d, 21e, 36f, 35g, 34h, 29i, 118j, 125k, 123l, 107m, 126n, 119o, 114p, 181q, 194r, 190s, 159t, 192u, 178v, 191w, 161x, 49Ω, 51α, 57μ, 54Ф, and 52π HIV-1-infected children and adolescents from the study cohort. Significant differences when p<0.05. NS, not significant (p>0.05). VL suppression refers to patients with available VL data who reached non-detectable VL (<500 c/ml) post initiation of LPV/r in at least one determination during LPV/r exposure, even if they later rebounded.